Cervical cancer screening following prophylactic human papillomavirus vaccination.
about
Human papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspectiveHuman papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)Distribution of high and low risk HPV types by cytological status: a population based study from Italy.Cervicovaginal cytology in patients undergoing pelvic radiotherapy using the Focalpoint system: results from the RODEO study.Systematic review of model-based cervical screening evaluations.Oncogenic HPV Types Infection in Adolescents and University Women from North Portugal: From Self-Sampling to Cancer Prevention.Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.EUROGIN 2011 roadmap on prevention and treatment of HPV-related diseaseLaboratory and clinical aspects of human papillomavirus testingOptimizing technology for cervical cancer screening in high-resource settings.A Suggested Approach to Simplify and Improve Cervical Screening in the United States.Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL StudyCervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.Early detection of cervical carcinomas: finding an overall approachMultiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.Market survey predictions on the future of US Pap testing.How to evaluate emerging technologies in cervical cancer screening?Knowledge of Greek adolescents on human papilloma virus (HPV) and vaccination: A national epidemiologic study.Prophylactic HPV vaccines: the Finnish perspective.Eurogin 2010 roadmap on cervical cancer prevention.Impact of HPV immunization on the detection of cervical disease.Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.Prospective parallel randomized trial of the MultiCyte™ ThinPrep(®) imaging system: the Scottish experience.Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control.Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings.Diagnostic Value of the CareTM HPV Test in Screening for Cervical Intraepithelial Neoplasia Grade 2 or WorseSynthesizing Evidence from Diagnostic Accuracy TEsts: the SEDATE guideline.Characterization of human papillomavirus genotypes and HPV-16 physical status in cervical neoplasias of women from northern Portugal.Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases.Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.Population-based case-control study on DAPK1, RAR-β2 and MGMT methylation in liquid-based cytology.Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.Personalized cancer screening: helping primary care rise to the challenge.Human papillomavirus vaccination and screening as the new paradigm in cervical cancer prevention
P2860
Q26799791-FD7B4B92-1ECC-4776-9851-71E28527216CQ30878077-70F6977F-AFC3-4A33-83CB-1A3D4C7BA3BEQ33545461-DB6805D1-02E3-42DA-BA13-2AFD14F08D98Q34573950-E7589CDE-DC41-4C99-BF92-F9E22B6A85E8Q35005042-405AC4CF-D9BA-4E67-8BFF-7B6AEEDF453BQ35568922-82429B34-B7E2-411E-918B-5DCA92E1C29DQ35585448-50AC7D93-D917-4F1A-BF16-C4E73F0D48B8Q36057298-4FEA3517-4E56-49CD-9C98-7B789E7E219EQ36194955-C3B94E49-150C-49E7-AFFE-7A917145493EQ36311573-4AB555C0-7DA6-4392-9376-B736AF69C36BQ36319941-9BBF01D2-7E20-4A58-AAB2-3C9163707EBBQ36407125-E74069A5-218D-48E1-A702-7303394A4AC9Q36451743-ACC3BE7B-1761-499E-AE17-EB26BAA0810AQ36679762-9FC8022B-4738-4485-82B6-2A4C977BC97CQ37147012-4B3B3E36-830B-4C2B-BE99-D8105B319FD8Q37170521-9F645EF3-E6A9-4976-A228-799E3BD33DB9Q37188108-00D69058-1AEF-4A45-8756-38761B8008A1Q37371137-FD77056C-B15E-4FF4-8ED6-BB2BA33344F5Q37377909-B5BB7F3D-234E-4549-B1DC-404001E62C2DQ37467429-F1D4AE1A-AE84-41F8-A452-927AFF5BEEA1Q37582542-E432E301-9441-4A03-81D6-FA8A8724A539Q37658879-D1F9EFFC-ED9D-442B-880E-97C291AD9181Q37826158-5A1C6672-CFF5-4096-A946-041FA86A66F4Q38194249-E81AB1B0-7F90-487F-B452-86D49B31F810Q39553769-4A1F399E-9351-4DDE-BE28-EE128F07B19AQ39614702-FA20D847-F09C-4163-9437-8DD7104264A1Q39807848-AB27C428-DD79-438C-9042-B7D579ED4B45Q40129828-21773DE7-C3F7-47F5-9E57-C56FF7EE0432Q40238624-AAE0D43E-80AD-4751-9C56-82EB4813706BQ40495140-00072FD7-09DD-42BF-9115-DE413DBA9047Q42237918-2F3DEF5F-51A3-4F58-9C99-DC9A2DB50112Q43210191-52EE595F-F2F7-4C3C-AD21-4AF57E8ED2E0Q48030944-B99F377D-027C-4D0A-AA23-09CE310EABFFQ51384082-81003607-AA04-4A82-A86B-81AB28E68627Q53290879-C807011A-0B1C-421F-A706-6ECF730E895CQ54965951-7C39E530-BADC-472D-B615-2380C80AF29AQ57089376-50381D3B-AFA8-4E2A-AC33-EDF2A506A2E6
P2860
Cervical cancer screening following prophylactic human papillomavirus vaccination.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@en
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@nl
type
label
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@en
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@nl
prefLabel
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@en
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@nl
P1433
P1476
Cervical cancer screening following prophylactic human papillomavirus vaccination.
@en
P2093
Jack Cuzick
P304
P356
10.1016/J.VACCINE.2007.11.069
P407
P478
26 Suppl 1
P577
2008-03-01T00:00:00Z